Belay Diagnostics

Belay Diagnostics provides next-gen sequencing to detect aneuploidy and mutations with our cerebrospinal fluid testing platform. Improving diagnosis for brain and spinal cord cancers can give people the best chance for a cure without the need for invasive biopsies. We see our technological advances in cerebrospinal fluid assays as offering clinicians alternative diagnostic tools for use in treatment decisions

Belay diagnostics operates in the Biotechnology research industry.

Belay diagnostics's revenue is 11m - 100m

Belay diagnostics has 11 - 50 employees.